Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy

BACKGROUND: Most gastrointestinal stromal tumors (GIST) driven by KIT or platelet‐derived growth factor receptor A (PDGFRA) mutations develop resistance to available tyrosine kinase inhibitor (TKI) treatments. NAVIGATOR is a two‐part, single‐arm, dose escalation and expansion study designed to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Suzanne, Jones, Robin L., Bauer, Sebastian, Kang, Yoon‐Koo, Schöffski, Patrick, Eskens, Ferry, Mir, Olivier, Cassier, Phillipe A., Serrano, Cesar, Tap, William D., Trent, Jonathan, Rutkowski, Piotr, Patel, Shreyaskumar, Chawla, Sant P., Meiri, Eval, Gordon, Michael, Zhou, Teresa, Roche, Maria, Heinrich, Micahel C., von Mehren, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018324/
https://www.ncbi.nlm.nih.gov/pubmed/33453089
http://dx.doi.org/10.1002/onco.13674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018324/
https://www.ncbi.nlm.nih.gov/pubmed/33453089
http://dx.doi.org/10.1002/onco.13674

Ejemplares similares